Skip to main content

Prevymis FDA Approval History

FDA Approved: Yes (First approved November 8, 2017)
Brand name: Prevymis
Generic name: letermovir
Dosage form: Tablets and Injection
Company: Merck
Treatment for: CMV Prophylaxis

Prevymis (letermovir) is a CMV DNA terminase complex inhibitor indicated for the prophylaxis of cytomegalovirus (CMV) infection and disease in adult allogeneic hematopoietic stem cell transplant patients.

Development timeline for Prevymis

Nov  9, 2017Approval FDA Approves Prevymis (letermovir) for Prevention of Cytomegalovirus (CMV) Infection and Disease in Adult Allogeneic Stem Cell Transplant Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.